CYLD and lymphoma: Collectively, our findings demonstrate that loss of CYLD renders BCR-dependent lymphoma cell lines less sensitive to BCR pathway inhibition by ibrutinib and sotrastaurin, indicating that their inhibitory effects on proliferation and signaling are at least partially dependent upon CYLD.